Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus ABCAMRF 84 Days Sales Outstanding is 63.44 as of Jun. 2026, which is 18% above its 10-year median of 53.63. GuruFocus rates CAMRF with a GF Score™ of 84/100 and a GF Value™ of $74.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 837 Biotechnology companies, Camurus AB ranks worse than 55.79% on this metric.
Camurus AB's average Accounts Receivable for the
three
months ended in Jun. 2026 was $51.3 Mil. Camurus AB's Revenue for the
three
months ended in Jun. 2026 was $73.8 Mil.
Hence, Camurus AB's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 63.44.
The historical rank and industry rank for Camurus AB's Days Sales Outstanding or its related term are showing as below:
CAMRF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.63 Med: 53.63 Max: 77.97
Current: 77.97
During the past 13 years, Camurus AB's highest Days Sales Outstanding was 77.97. The lowest was 27.63. And the median was 53.63.
CAMRF's Days Sales Outstanding is ranked worse than 55.79% of 837
companies
in the Biotechnology industry
Industry Median: 69.03
vs CAMRF: 77.97
Camurus AB's Days Sales Outstanding
declined
from Jun. 2025 (66.91) to Jun. 2026 (63.44).
Camurus AB (OTCPK:CAMRF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Camurus AB Days Sales Outstanding Related Terms
Camurus AB Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Camurus AB's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Camurus AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Camurus AB's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Days Sales Outstanding of 63.44 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Camurus AB and its competitors. This is 18% above median its historical median of 53.63. Over the past decade, Camurus AB's Days Sales Outstanding has ranged from 27.63 to 77.97. According to the industry distribution chart, Camurus AB ranks #467 out of 837 companies in the Biotechnology industry, placing it in the top 55.8%.
Is Camurus AB's Days Sales Outstanding too high?
Camurus AB's current Days Sales Outstanding of 63.44 is 18% above median its 10-year median of 53.63. Over the past 10 years, this metric has ranged from a low of 27.63 to a high of 77.97. The Biotechnology industry median Days Sales Outstanding is 69.03. Camurus AB's value of 63.44 is 8.1% below this industry median. Based on the distribution chart, Camurus AB ranks #467 out of 837 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Camurus AB has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #467 out of 837 companies for Days Sales Outstanding. This places Camurus AB in the lower half of its industry. The industry median Days Sales Outstanding is 69.03. Camurus AB's value of 63.44 is 8.1% below this benchmark. Historically, Camurus AB's own Days Sales Outstanding has ranged from 27.63 to 77.97 over the past decade. While the company's 10-year median is 53.63 vs. the industry median of 69.03, Camurus AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.03, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Days Sales Outstanding of 63.44 is 8.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Days Sales Outstanding is 63.44, which is 18% above median its own 10-year median of 53.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $74.58, compared to a current price of $58.51 — trading 21.5% below its estimated fair value. The current Days Sales Outstanding is 63.44, which is 18% above median its 10-year median of 53.63 and 8.1% below the Biotechnology industry median of 69.03. Camurus AB's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Days Sales Outstanding is 63.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $58.51 is trading 21.5% below its estimated GF Value™ of $74.58.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Days Sales Outstanding: 63.44 (18% above median its 10-year median of 53.63)
GF Value™: $74.58 vs. price of $58.51 (21.5% below fair value)
Industry Position: 8.1% below the Biotechnology median (#467 of 837)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
84GF Score
Get the complete analysis for CAMRF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
